证券代码：300138 证券简称：晨光生物 公告编号：2025—086 晨光生物科技集团股份有限公司 二、对外担保进展情况 公司对子公司银行借款担保情况发生了变动，具体情况如下： （一）子公司归还银行借款暨担保义务减少情况 结合自身经营流动资金需求，经公司 2023 年年度股东大会决议，晨光生物 科技集团图木舒克有限公司（以下简称"图木舒克晨光"，系新疆晨光生物科技 股份有限公司全资子公司，穿透后为公司控股子公司）前期向招商银行股份有限 关于为子公司银行借款提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 晨光生物科技集团股份有限公司（简称"公司"）于 2025 年 4 月 3 日召开 第五届董事会第十五次会议、2025 年 5 月 6 日召开 2024 年年度股东大会，审议 通过了《关于公司与子公司或子公司之间融资担保的议案》，同意公司及合并报 表范围内各级子公司在2024年年度股东大会审议通过之日起至2025年年度股东 大会召开日，向融资机构申请办理各类融资业务余额不超 70 亿元；融资担保方 式涉及公司合并报表范围内各 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—085 晨光生物科技集团股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）于 2025 年 8 月 24 日召开的第五届董事会第十八次会议、第五届监事会第十七次会议审议通过了 《关于使用部分暂时闲置募集资金进行现金管理的议案》。同意公司在不影响募 集资金投资项目建设的前提下，使用不超过 5,000 万元暂时闲置募集资金进行现 金管理，用于购买安全性高、流动性好的理财产品/结构性存款产品等，不得购 买非保本型理财产品，期限为自本次董事会审议通过之日起不超过 12 个月，期 限内在上述资金额度范围内滚动使用（详见 2025 年 8 月 26 日披露于巨潮资讯网 的《关于使用部分暂时闲置募集资金进行现金管理的公告》）。 因募集资金现金管理需要，公司开立了募集资金现金管理产品专用结算账户， 具体信息如下： | 晨光生物科技集团股份有限公司 | 中国建设银行股份有限公司 | 1305011093980 ...

证券日报网讯晨光生物（300138）8月27日在互动平台回答投资者提问时表示，2025年以来公司棉籽类 业务销量良好，截至2025年上半年末，存货账面价值同比大幅降低，是公司合并报表存货减少的主要原 因。 ...

Financial Performance - In the first half of 2025, the company achieved revenue of 3.658 billion CNY, a year-on-year increase of 4.77% [2] - Net profit attributable to shareholders reached 215 million CNY, representing a significant year-on-year growth of 115.33% [2] - Revenue from plant extraction products amounted to 1.733 billion CNY, with a year-on-year increase of 9.47% and a gross margin of 20.24%, up by 3.43% [2] Product Performance - Sales of the main product, chili red pigment, reached 6,367 tons, a year-on-year increase of 43% [3] - Chili extract sales grew to 1,536 tons, marking an 81% increase [3] - Lutein sales remained stable while promoting high-value products, with a focus on application-specific products [3] - Revenue from stevia glycosides exceeded 160 million CNY, driven by innovative processes [4] Business Strategy - The company adopted a "locking" strategy for cottonseed business to mitigate price volatility, achieving revenue of 1.765 billion CNY, a 2% increase [4] - The company plans to enhance market share for chili extract without immediate price increases, focusing on extending the processing chain [5] - The company aims to develop stevia and other tiered products into new major products, indicating significant growth potential [6] Research and Development - R&D expenses increased significantly due to changes in project structure and material costs, reflecting the company's commitment to innovation [9] - The company will continue to invest heavily in R&D while balancing costs and profits to ensure sustainable growth [9] Market Expansion - The company plans to expand its marigold planting in Myanmar, aiming to establish it as a key raw material source for lutein [7] - The company is enhancing its raw material supply chain by supporting suppliers and stabilizing market supply [8]

Core Viewpoint - The recent financial report of Morning Light Bio (300138) shows significant growth in revenue and net profit, indicating improved profitability and operational efficiency. Financial Performance - As of the end of the reporting period, the company's total revenue reached 3.658 billion yuan, a year-on-year increase of 4.77% [1] - The net profit attributable to shareholders was 215 million yuan, up 115.33% year-on-year [1] - In Q2, total revenue was 1.941 billion yuan, reflecting a 10.38% increase year-on-year, while net profit for the quarter was 105 million yuan, up 72.25% [1] - Gross margin improved to 13.86%, a year-on-year increase of 67.4%, and net margin rose to 6.05%, up 125.15% [1] - Total expenses (selling, administrative, and financial) amounted to 156 million yuan, accounting for 4.28% of revenue, a decrease of 0.44% year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased to 0.44 yuan, a rise of 131.58% year-on-year [1] - Operating cash flow per share reached 3.79 yuan, up 95.33% year-on-year [1] - The company's return on invested capital (ROIC) was 1.91%, indicating weak capital returns [1] - The debt-to-asset ratio for interest-bearing liabilities reached 56.97% [4] Business Model and Strategy - The company's performance is primarily driven by research and development, necessitating a thorough examination of the underlying drivers [3] - The company is focusing on the trend of replacing synthetic colors with natural colors, which presents significant opportunities in the natural color industry [7] Market Position and Investor Interest - Several funds have recently increased their holdings in Morning Light Bio, indicating growing investor interest [6] - The largest fund holding the company is Wan Jia Domestic Demand Growth Mixed Fund, with a scale of 530 million yuan [6]

证券研究报告 晨光生物 (300138 CH) 业绩加速修复，植提份额提升 华泰研究 中报点评 投资评级(维持): 增持 资料来源：Wind 经营预测指标与估值 | 目标价(人民币): | 17.76 | | --- | --- | | 吕若晨 | 研究员 | | SAC No. S0570525050002 | lvruochen@htsc.com | | SFC No. BEE828 | +(86) 755 8249 2388 | 倪欣雨 研究员 SAC No. S0570523080004 SFC No. BVQ058 nixinyu@htsc.com +(86) 21 2897 2228 基本数据 | 目标价 (人民币) | 17.76 | | --- | --- | | 收盘价 (人民币 截至 8 月 25 日) | 14.20 | | 市值 (人民币百万) | 6,860 | | 6 个月平均日成交额 (人民币百万) | 178.46 | | 52 周价格范围 (人民币) | 7.00-14.20 | | BVPS (人民币) | 6.75 | 股价走势图 (6) 20 47 73 99 Aug- ...

Investment Rating - The report maintains an "Outperform" rating for the company, indicating a positive outlook for its stock performance relative to the market [5]. Core Insights - The company reported a total revenue of 3.66 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.77%, with a net profit attributable to shareholders of 215 million yuan, a significant increase of 115.3% [5]. - The company is actively adjusting its cottonseed business, benefiting from rising cottonseed protein prices, which is expected to enhance profitability [5]. - The core business of plant extraction is at the bottom of the price cycle, with completed inventory reserves aimed at improving price and market share advantages [5]. - The company has seen a continuous increase in market penetration for its chili products and is steadily expanding its new product categories [5]. Financial Data and Profit Forecast - The total revenue forecast for 2025 is 7.166 billion yuan, with a projected year-on-year growth rate of 2.5% [4]. - The net profit attributable to shareholders is expected to reach 324 million yuan in 2025, representing a substantial year-on-year growth of 244.3% [4]. - The earnings per share (EPS) is projected to be 0.67 yuan for 2025, with a corresponding price-to-earnings (PE) ratio of 21x [4]. - The gross margin for the plant extraction business is expected to improve, with a forecasted gross margin of 10.0% for 2025 [4]. Business Performance Highlights - In Q2 2025, the company achieved a revenue of 1.94 billion yuan, marking a year-on-year increase of 10.4%, with a net profit of 105 million yuan, up 72.3% [5]. - The company’s main products, such as chili red and chili extract, have seen significant sales growth, with volumes increasing by 43% and 81% respectively [5]. - The company has successfully optimized its raw material supply structure for lutein, with sales in the feed-grade segment exceeding 210 million grams, showing a slight increase [5]. - The spice division has also performed well, with sales of Sichuan pepper extract growing by approximately 23% [5].

Core Viewpoint - The company has approved a hedging business to mitigate risks associated with price fluctuations of raw materials and related products, using its own funds not exceeding 46 million yuan [1][2][3] Group 1: Hedging Business Details - The hedging business will focus on futures related to cottonseed and its products, including cotton oil and cotton meal/protein, as well as soybean meal futures [2] - The investment amount is capped at 46 million yuan, which includes margin and risk funds, with a maximum contract value of 650 million yuan on any trading day [2] - The trading will occur on legally operating futures exchanges within China, using self-owned funds without involving raised capital [2] Group 2: Risk Management and Oversight - The hedging business is intended solely to reduce risks from price fluctuations and not for profit-making purposes [2] - The company has established a risk management system to control market, technical, and policy risks, including regular audits by the audit department and oversight by the audit committee [2][3] - The supervisory board supports the hedging initiative, affirming that it aligns with legal and regulatory requirements and does not harm the interests of shareholders, particularly minority shareholders [3]

每经头条（nbdtoutiao）——租下2.5万亩"试验田"，兽医学博士在非洲种粮：首季亩产250斤，打算扩至 10万亩，月薪1~2万元招人 2024年1至12月份，晨光生物的营业收入构成为：农副食品加工业(植物提取物)占比100.0%。 每经AI快讯，晨光生物（SZ 300138，收盘价：14.2元）8月25日晚间发布公告称，公司第五届第十八次 董事会会议于2025年8月24日在公司会议室以现场与通讯相结合的方式召开。会议审议了《关于聘任公 司总经理的议案》等文件。 （记者 张喜威） ...

智通财经APP讯，晨光生物(300138.SZ)发布2025年半年度报告，报告期内，公司实现营业收入36.58亿 元，同比增长4.77%。实现归属于上市公司股东的净利润2.15亿元，同比增长115.33%。实现归属于上市 公司股东的扣除非经常性损益的净利润1.84亿元，同比增长130.48%。基本每股收益0.44元。 ...